Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138561

Published: 2020

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD

Blood (2018) 132 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2018-99-113935

Published: 2018

Journal Articles

Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML)

Matthew J. Wieduwilt, MD PhD, Jan Cerny, MD PhD, Luke Akard, MD, Celalettin Ustun, MD, Farhad Ravandi, MD, James M. Rossetti, DO, Brian T. Hill, MD PhD, Janice (Wes) Brown, MD, Lois Kellerman, Rod Van Syoc, William Reed, MD, Charalambos Andreadis, MD MSCE

Blood (2014) 124 (21): 2268.

https://doi.org/10.1182/blood.V124.21.2268.2268

Published: 2014

Journal Articles

Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS

Guillermo Garcia Manero, MD, Luger Selina, MD, Klimek Virginia, MD, Cooper Maureen, MD, Emmanuel C. Besa, MD, James M. Rossetti, DO, Richard Chao, MD, Rachel Humphrey, Lewis R. Silverman, MD

Blood (2013) 122 (21): 1550.

https://doi.org/10.1182/blood.V122.21.1550.1550

Published: 2013

Journal Articles

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Heather L. Benjamin, MD, James M. Rossetti, DO, Aaron J. Lampkin, MSIV, Christie Hilton, DO, Entezam Sahovic, MD, Haifaa Abdulhaq, Richard K. Shadduck, MD, Namratha Vemulapalli, MD, Amanda Hercules, MD, John Lister, MD

Blood (2009) 114 (22): 4164.

https://doi.org/10.1182/blood.V114.22.4164.4164

Published: 2009

Journal Articles

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

Haifaa Abdulhaq, MD, Bushra Haq, MD, James M. Rossetti, DO, Richard K. Shadduck, MD, Entezam Sahovic, MD, Dijana Christianson, DO, John Lister, MD

Blood (2008) 112 (11): 5072.

https://doi.org/10.1182/blood.V112.11.5072.5072

Published: 2008

Journal Articles

A Retrospective Analysis of Response to High Dose Rituximab Monotherapy in CLL/NHL Patients Who Received Prior Standard Dose Rituximab Therapy.

Casey A. Moffa, DO, Chandana Thatikonda, MBBS, Neeta Pathe, MD, James M. Rossetti, DO, Richard K. Shadduck, MD, John Lister, MD

Blood (2007) 110 (11): 4722.

https://doi.org/10.1182/blood.V110.11.4722.4722

Published: 2007

Journal Articles

Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation.

James M. Rossetti, DO, Richard K. Shadduck, MD, Chandana Thatikonda, MBBS, Entezam Sahovic, MD, John Lister, MD

Blood (2007) 110 (11): 5034.

https://doi.org/10.1182/blood.V110.11.5034.5034

Published: 2007

Journal Articles

Combination Methyltransferase and Histone Deacetylase Inhibition in Elderly Patients with Secondary Acute Myelogenous Leukemia.

Chandanda Thatikonda, MBBS, James M. Rossetti, DO, Richard K. Shadduck, MD, John Lister, MD

Blood (2007) 110 (11): 4387.

https://doi.org/10.1182/blood.V110.11.4387.4387

Published: 2007

Journal Articles

G-CSF Increases Hematological Response among Patients with Myelodysplasia Treated with Azacitidine.

James M. Rossetti, DO, Eric Falke, Richard K. Shadduck, MD, Joan M. Latsko, MSN, CRNP, AOCNP, Wendy Kramer, John Lister, MD

Blood (2006) 108 (11): 4868.

https://doi.org/10.1182/blood.V108.11.4868.4868

Published: 2006

NARROW

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML)

Combination Therapy With Mocetinostat, An Oral, Spectrum-Selective Histone Deacetylase (HDAC) Inhibitor, and 5-Azaciditine: Indication Of Clinical Activity In MDS

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

A Retrospective Analysis of Response to High Dose Rituximab Monotherapy in CLL/NHL Patients Who Received Prior Standard Dose Rituximab Therapy.

Low-Dose Azacitidine for Relapse of MDS/AML after Unrelated Donor Peripheral Blood Stem Cell Transplantation.

Combination Methyltransferase and Histone Deacetylase Inhibition in Elderly Patients with Secondary Acute Myelogenous Leukemia.

G-CSF Increases Hematological Response among Patients with Myelodysplasia Treated with Azacitidine.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only